



Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021

March 11, 2021

Presentations Highlight Continued Progress Across Expanded R&D Pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors

REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced the company will make six presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 being held April 10-15, 2021 in a virtual format.

Details of the planned presentations are as follows:

Oral Presentation:

Title: [Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers](#)

Abstract Number: LB001

Session: Late-Breaking Minisymposium 1

Date/Time: April 10, 2021 at 2:05 p.m. Eastern

Poster Presentations:

Title: [First-in-class, orally bioavailable KRAS^{G12V}\(ON\) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRAS^{G12V} mutant cancers](#)

Abstract Number: 1260

Session: Novel Antitumor Agents

Date/Time: April 10, 2021 at 8:30 a.m. Eastern

Title: [A next generation tri-complex KRAS^{G12C}\(ON\) inhibitor directly targets the active, GTP-bound state of mutant RAS and may overcome resistance to KRAS^{G12C}\(OFF\) inhibition](#)

Abstract Number: 1261

Session: Novel Antitumor Agents

Date/Time: April 10, 2021 at 8:30 a.m. Eastern

Title: [Discovery of a potent, selective, and orally bioavailable SOS1 inhibitor, RMC-023, an *in vivo* tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction](#)

Abstract Number: 1273

Session: Novel Antitumor Agents

Date/Time: April 10, 2021 at 8:30 a.m. Eastern

Title: [Modulation of innate and adaptive immunity in blood and tumor of patients receiving the SHP2 inhibitor RMC-4630](#)

Abstract Number: LB050

Session: Immune Response to Therapies

Date: April 10, 2021 at 8:30 a.m. Eastern

Title: [Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical study](#)

Abstract Number: LB054

Session: Liquid Biopsies: Circulating DNA

Date: April 10, 2021 at 8:30 a.m. Eastern

Additional information on the AACR Annual Meeting 2021 is available through the AACR website at: <https://www.aacr.org/meeting/aacr-annual-meeting-2021/>

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding Revolution Medicines' progress across its R&D pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Revolution Medicines' programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Revolution Medicines' ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Revolution Medicines' capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines' Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2021, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Contacts: For Investors: Vida Strategic Partners Stephanie Diaz 415-675-7401 sdiaz@vidasp.com For Media: Vida Strategic Partners Tim Brons 415-675-7402 tbrons@vidasp.com